Neuroblastoma between 1990 and 2014 in the Netherlands: Increased incidence and improved survival of high-risk neuroblastoma

Tas, Michelle L.; Reedijk, Ardine M.J.; Karim‐Kos, Henrike E.; Kremer, Leontien C. M.; Ven, Cornelis P. van de; Dierselhuis, Miranda P.; Eijkelenburg, Natasha K. A. van; Grotel, Martine van; Kraal, Kathelijne C.J.M.; Peek, Annemarie M.L.; Coebergh, Jan Willem; Janssens, Geert O.; Keizer, Bart de; Krijger, Ronald R. de; Pieters, Rob; Tytgat, Godelieve A.M.; Noesel, Max M. van

doi:10.1016/j.ejca.2019.09.025

Cited by 47 publications

(40 citation statements)

References 33 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neuroblastoma (NB) is the most common extracranial solid tumor occurring in children 1 . Over 75% of patients are categorized as high-risk with a poor overall 5-year survival of less than 50%, despite intensive treatment with high-dose chemotherapy followed by surgery, autologous stem cell transplantation, radiotherapy and immunotherapy 2 , 3 . Resection of high-risk NB is associated with a risk for serious surgical complications, since the tumor often encases major blood vessels leading to severe hemorrhage and/or unplanned organ damage 4 , 5 .…”

Section: Introductionmentioning

confidence: 99%

Anti-GD2-IRDye800CW as a targeted probe for fluorescence-guided surgery in neuroblastoma

Wellens

Deken

Sier

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Neuroblastoma resection represents a major challenge in pediatric surgery, because of the high risk of complications. Fluorescence-guided surgery (FGS) could lower this risk by facilitating discrimination of tumor from normal tissue and is gaining momentum in adult oncology. Here, we provide the first molecular-targeted fluorescent agent for FGS in pediatric oncology, by developing and preclinically evaluating a GD2-specific tracer consisting of the immunotherapeutic antibody dinutuximab-beta, recently approved for neuroblastoma treatment, conjugated to near-infrared (NIR) fluorescent dye IRDye800CW. We demonstrated specific binding of anti-GD2-IRDye800CW to human neuroblastoma cells in vitro and in vivo using xenograft mouse models. Furthermore, we defined an optimal dose of 1 nmol, an imaging time window of 4 days after administration and show that neoadjuvant treatment with anti-GD2 immunotherapy does not interfere with fluorescence imaging. Importantly, as we observed universal, yet heterogeneous expression of GD2 on neuroblastoma tissue of a wide range of patients, we implemented a xenograft model of patient-derived neuroblastoma organoids with differential GD2 expression and show that even low GD2 expressing tumors still provide an adequate real-time fluorescence signal. Hence, the imaging advancement presented in this study offers an opportunity for improving surgery and potentially survival of a broad group of children with neuroblastoma.

show abstract

Section: Introductionmentioning

confidence: 99%

Anti-GD2-IRDye800CW as a targeted probe for fluorescence-guided surgery in neuroblastoma

Wellens

Deken

Sier

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“… 1 The incidence of neuroblastoma is about 11–13 in 1 million among children less than 15 years old in developed countries. 2 In China, neuroblastoma represents approximately 10% of childhood tumors, with an incidence of approximately 7.7 cases per 1 million children. 3 Neuroblastoma is the primary cause of cancer death in childhood, accounting for approximately 15% of all pediatric cancer mortality.…”

Section: Introductionmentioning

confidence: 99%

METTL14 Gene Polymorphisms Confer Neuroblastoma Susceptibility: An Eight-Center Case-Control Study

Zhang

Zhu

et al. 2020

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

Neuroblastoma is the primary cause of cancer death in childhood. METTL14 is tightly linked to cancer. However, whether single-nucleotide polymorphisms (SNPs) in the METTL14 gene could predispose to neuroblastoma susceptibility lacks evidence. With an epidemiology case-control study, associations between METTL14 gene SNPs and overall risk for neuroblastoma were estimated in 898 cases and 1,734 controls. Following that, stratified analysis was performed. Among the five analyzed SNPs, rs298982 G>A and rs62328061 A>G exhibited a significant association with decreased susceptibility to neuroblastoma, whereas the associations with increased neuroblastoma susceptibility were observed for rs9884978 G>A and rs4834698 T>C. Moreover, subjects carrying two to five risk genotypes were more inclined to develop neuroblastoma than those with zero to one risk genotypes. The stratified analysis further demonstrated the protective effect of rs298982 G>A and rs62328061 A>G, as well as the predisposing effect of rs4834698 T>C and two to five risk genotypes, in certain subgroups. Haplotype analysis was performed. Moreover, false-positive report probability analysis validated the reliability of the significant results. The expression quantitative trait locus analysis revealed that rs298982 is correlated with the expression levels of its surrounding genes. Our results suggest that some SNPs in the METTL14 gene are associated with predisposition to neuroblastoma.

show abstract

“…Survival rate could be achieved at least 95% in patients with a non–high‐risk (low‐ and intermediate‐risk) neuroblastoma 8 . Conversely, only 50% of patients with high‐risk neuroblastoma achieve long‐term survival 9,10 …”

Section: Introductionmentioning

confidence: 99%

Association between METTL3 gene polymorphisms and neuroblastoma susceptibility: A nine‐centre case‐control study

Bian

Zhang

Zhu

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

Neuroblastoma ranks as the most commonly seen and deadly solid tumour in infancy. The aberrant activity of m 6 A‐RNA methyltransferase METTL3 is involved in human cancers. Therefore, functional genetic variants in the METTL3 gene may contribute to neuroblastoma risk. In the current nine‐centre case‐control study, we aimed to analyse the association between the METTL3 gene single nucleotide polymorphisms (SNPs) and neuroblastoma susceptibility. We genotyped four METTL3 gene SNPs (rs1061026 T>G, rs1061027 C>A, rs1139130 A>G, and rs1263801 G>C) in 968 neuroblastoma patients and 1814 controls in China. We found significant associations between these SNPs and neuroblastoma risk in neither single‐locus nor combined analyses. Interestingly, in the stratified analysis, we observed a significant risk association with rs1061027 AA in subgroups of children ≤ 18 months of age (adjusted OR = 1.87, 95% CI = 1.03‐3.41, P = .040) and females (adjusted OR = 1.86, 95% CI = 1.07‐3.24, P = .028). Overall, we identified a significant association between METTL3 gene rs1061027 C>A polymorphism and neuroblastoma risk in children ≤18 months of age and females. Our findings provide novel insights into the genetic determinants of neuroblastoma.

show abstract

Neuroblastoma between 1990 and 2014 in the Netherlands: Increased incidence and improved survival of high-risk neuroblastoma

Cited by 47 publications

References 33 publications

Anti-GD2-IRDye800CW as a targeted probe for fluorescence-guided surgery in neuroblastoma

Anti-GD2-IRDye800CW as a targeted probe for fluorescence-guided surgery in neuroblastoma

METTL14 Gene Polymorphisms Confer Neuroblastoma Susceptibility: An Eight-Center Case-Control Study

Association between METTL3 gene polymorphisms and neuroblastoma susceptibility: A nine‐centre case‐control study

Contact Info

Product

Resources

About